Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 November 1998:
Vol. 282. no. 5393, p. 1404
DOI: 10.1126/science.282.5393.1404
Prev | Table of Contents | Next

News Focus

MICROBIOLOGY:
Training a Molecular Gun on Killer E. coli

Richard A. Lovett

Researchers at the National Institutes of Health are closing in on the development of the first vaccine against Escherichia coli O157:H7, a pathogenic version of the common gut bacterium. Tests of an experimental vaccine showed promise in adults earlier this year, and the researchers are about to apply for approval to test it in young children. If the trial gets the go-ahead and the preparation passes further tests, experts say, a vaccine for people and one for livestock could be available early next century.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Bacterial Ghosts as an Oral Vaccine: a Single Dose of Escherichia coli O157:H7 Bacterial Ghosts Protects Mice against Lethal Challenge.
U. B. Mayr, C. Haller, W. Haidinger, A. Atrasheuskaya, E. Bukin, W. Lubitz, and G. Ignatyev (2005)
Infect. Immun. 73, 4810-4817
   Abstract »    Full Text »    PDF »
P1 Trisaccharide (Gal{alpha}1,4Gal{beta}1,4GlcNAc) Synthesis by Enzyme Glycosylation Reactions Using Recombinant Escherichia coli.
Z. Liu, Y. Lu, J. Zhang, K. Pardee, and P. G. Wang (2003)
Appl. Envir. Microbiol. 69, 2110-2115
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)